These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. Farrell R; Bendtzen K; Bertolotto A; Clark B; Comabella M; Deisenhammer F; Fogdell-Hahn A; Giovannoni G; Hartung HP; Hemmer B; Hillert J; Kappos L; Killestein J; Lindberg R; Montalban X; Polman C; Sorensen PS; J Int Med Res; 2008; 36(1):204-8; author reply 208-10. PubMed ID: 18230281 [No Abstract] [Full Text] [Related]
48. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Schwid SR; Decker MD; Lopez-Bresnahan M; Neurology; 2005 Dec; 65(12):1964-6. PubMed ID: 16380621 [TBL] [Abstract][Full Text] [Related]
49. Access denied. While the decision over beta-interferon prescribing hangs in the balance, one thing's for certain--nurses will be left to pick up the pieces. Thomas S Nurs Stand; 2000 Jul 19-25; 14(44):20. PubMed ID: 11975272 [No Abstract] [Full Text] [Related]
51. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Francis GS; Rice GP; Alsop JC; Neurology; 2005 Jul; 65(1):48-55. PubMed ID: 16009884 [TBL] [Abstract][Full Text] [Related]
52. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320 [TBL] [Abstract][Full Text] [Related]
53. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Byrne E Neurology; 2003 Jun; 60(11):1872; author reply 1872-3. PubMed ID: 12796564 [No Abstract] [Full Text] [Related]
55. The REFLEX study: a missed opportunity? Giovannoni G Lancet Neurol; 2012 Jan; 11(1):22-4. PubMed ID: 22146410 [No Abstract] [Full Text] [Related]
56. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. Yushchenko M; Mäder M; Elitok E; Bitsch A; Dressel A; Tumani H; Bogumil T; Kitze B; Poser S; Weber F J Neurol; 2003 Oct; 250(10):1224-8. PubMed ID: 14586607 [TBL] [Abstract][Full Text] [Related]
57. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia]. Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137 [TBL] [Abstract][Full Text] [Related]
58. Diagnosis and disease modifying treatments in multiple sclerosis. Zajicek J Postgrad Med J; 2005 Sep; 81(959):556-61. PubMed ID: 16143683 [TBL] [Abstract][Full Text] [Related]
59. All people with MS have a right to be treated. Scott H Br J Nurs; 2000 Jul 13-26; 9(13):816. PubMed ID: 11261052 [No Abstract] [Full Text] [Related]
60. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies? Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]